These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 18366007)
1. Increased expression of matrix metalloproteinase-2 (MMP-2) predicts tumour recurrence and unfavourable outcome in non-small cell lung cancer. Leinonen T; Pirinen R; Böhm J; Johansson R; Kosma VM Histol Histopathol; 2008 Jun; 23(6):693-700. PubMed ID: 18366007 [TBL] [Abstract][Full Text] [Related]
2. Cyclooxygenase-2 expression is a prognostic biomarker for non-small cell lung cancer patients treated with adjuvant platinum-based chemotherapy. Shimizu K; Yukawa T; Okita R; Saisho S; Maeda A; Nojima Y; Nakata M World J Surg Oncol; 2015 Feb; 13():21. PubMed ID: 25888998 [TBL] [Abstract][Full Text] [Related]
3. Expression of matrix metalloproteinases 7 and 9 in non-small cell lung cancer. Relation to clinicopathological factors, beta-catenin and prognosis. Leinonen T; Pirinen R; Böhm J; Johansson R; Ropponen K; Kosma VM Lung Cancer; 2006 Mar; 51(3):313-21. PubMed ID: 16423426 [TBL] [Abstract][Full Text] [Related]
4. Clinical significance of IGF1R expression in non-small-cell lung cancer. Nakagawa M; Uramoto H; Oka S; Chikaishi Y; Iwanami T; Shimokawa H; So T; Hanagiri T; Tanaka F Clin Lung Cancer; 2012 Mar; 13(2):136-42. PubMed ID: 22133293 [TBL] [Abstract][Full Text] [Related]
5. Expression of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases in non-small-cell lung cancer. Suzuki M; Iizasa T; Fujisawa T; Baba M; Yamaguchi Y; Kimura H; Suzuki H Invasion Metastasis; 1998-1999; 18(3):134-41. PubMed ID: 10474026 [TBL] [Abstract][Full Text] [Related]
6. Prognostic effect of matrix metalloproteinase-9 in patients with resected Non small cell lung cancer. Lee CY; Shim HS; Lee S; Lee JG; Kim DJ; Chung KY J Cardiothorac Surg; 2015 Mar; 10():44. PubMed ID: 25888323 [TBL] [Abstract][Full Text] [Related]
7. Biological and prognostic role of acid cysteine proteinase inhibitor (ACPI, cystatin A) in non-small-cell lung cancer. Leinonen T; Pirinen R; Böhm J; Johansson R; Rinne A; Weber E; Kosma VM J Clin Pathol; 2007 May; 60(5):515-9. PubMed ID: 16790691 [TBL] [Abstract][Full Text] [Related]
8. Cellular localization of EMMPRIN predicts prognosis of patients with operable lung adenocarcinoma independent from MMP-2 and MMP-9. Sienel W; Polzer B; Elshawi K; Lindner M; Morresi-Hauf A; Vay C; Eder F; Passlick B; Klein CA Mod Pathol; 2008 Sep; 21(9):1130-8. PubMed ID: 18567995 [TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinase-2 status in stromal fibroblasts, not in tumor cells, is a significant prognostic factor in non-small-cell lung cancer. Ishikawa S; Takenaka K; Yanagihara K; Miyahara R; Kawano Y; Otake Y; Hasegawa S; Wada H; Tanaka F Clin Cancer Res; 2004 Oct; 10(19):6579-85. PubMed ID: 15475447 [TBL] [Abstract][Full Text] [Related]
10. Prognostic stratification of stage IIIA pN2 non-small cell lung cancer by hierarchical clustering analysis of tissue microarray immunostaining data: an Alpe Adria Thoracic Oncology Multidisciplinary Group study (ATOM 014). Grossi F; Spizzo R; Bordo D; Cacitti V; Valent F; Rossetto C; Follador A; Di Terlizzi S; Aita M; Morelli A; Fasola G; Consiglieri C; Ceschia T; Beltrami CA; Belvedere O J Thorac Oncol; 2010 Sep; 5(9):1354-60. PubMed ID: 20631638 [TBL] [Abstract][Full Text] [Related]
11. Elevated activities of MMP-2 in the non-tumorous lung tissues of curatively resected stage I NSCLC patients are associated with tumor recurrence and a poor survival. Kim SH; Choi HY; Lee J; Son DS; Lee HS; Song IS; Lim YS; Hong YS; Kim J; Choi YS J Surg Oncol; 2007 Mar; 95(4):337-46. PubMed ID: 17326127 [TBL] [Abstract][Full Text] [Related]
12. Association between cyclooxygenase-2 and matrix metalloproteinase-2 expression in non-small cell lung cancer. Byun JH; Lee MA; Roh SY; Shim BY; Hong SH; Ko YH; Ko SJ; Woo IS; Kang JH; Hong YS; Lee KS; Lee AW; Park GS; Lee KY Jpn J Clin Oncol; 2006 May; 36(5):263-8. PubMed ID: 16735371 [TBL] [Abstract][Full Text] [Related]
13. Overexpression of CHD1L is positively associated with metastasis of lung adenocarcinoma and predicts patients poor survival. He LR; Ma NF; Chen JW; Li BK; Guan XY; Liu MZ; Xie D Oncotarget; 2015 Oct; 6(31):31181-90. PubMed ID: 26360781 [TBL] [Abstract][Full Text] [Related]
14. High p-Smad2 expression in stromal fibroblasts predicts poor survival in patients with clinical stage I to IIIA non-small cell lung cancer. Chen Y; Xing P; Chen Y; Zou L; Zhang Y; Li F; Lu X World J Surg Oncol; 2014 Nov; 12():328. PubMed ID: 25373709 [TBL] [Abstract][Full Text] [Related]
15. Cyclooxygenase-2 expression is not a marker of poor survival in lung cancer. Turk HM; Camci C; Sevinc A; Bukyukberber S; Sari I; Adli M Asian Pac J Cancer Prev; 2012; 13(1):315-8. PubMed ID: 22502692 [TBL] [Abstract][Full Text] [Related]
16. Tyrosine-protein phosphatase non-receptor type 12 expression is a good prognostic factor in resectable non-small cell lung cancer. Cao X; Chen YZ; Luo RZ; Zhang L; Zhang SL; Zeng J; Jiang YC; Han YJ; Wen ZS Oncotarget; 2015 May; 6(13):11704-13. PubMed ID: 25868976 [TBL] [Abstract][Full Text] [Related]
17. Extent of lymphadenectomy and outcome for patients with stage I nonsmall cell lung cancer. Varlotto JM; Recht A; Nikolov M; Flickinger JC; Decamp MM Cancer; 2009 Feb; 115(4):851-8. PubMed ID: 19140203 [TBL] [Abstract][Full Text] [Related]
18. Bone marrow micrometastasis is associated with both disease recurrence and poor survival in surgical patients with node-negative non-small-cell lung cancer: a meta-analysis. Deng XF; Liu QX; Zhou D; Min JX; Dai JG Interact Cardiovasc Thorac Surg; 2015 Jul; 21(1):21-7. PubMed ID: 25883247 [TBL] [Abstract][Full Text] [Related]